English  |  正體中文  |  简体中文  |  2856655  
???header.visitor??? :  53549411    ???header.onlineuser??? :  1444
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"shaw a t"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-25 of 31  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-09-15T01:09:04Z Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.
臺大學術典藏 2022-09-15T01:09:00Z Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C.
臺大學術典藏 2022-09-15T01:08:57Z Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.
臺大學術典藏 2022-06-27T06:59:45Z Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T.
臺大學術典藏 2020-12-02T02:33:14Z Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al.
臺大學術典藏 2020-05-26T09:26:43Z Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer Ou S.-H.I.;Zeaiter A;Golding S;Bordogna W;Han J.-Y;Chih-Hsin Yang;Tessmer A;Dansin E;De Pas T;Crino L;Duruisseaux M;Moro-Sibilot D.L;Chiappori A;Kim D.-W;De Petris L;Camidge D.R;Socinski M.A;Gandhi L;Govindan R;Shaw A.T;Gadgeel S.M; Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:43Z Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer Ou S.-H.I.;Zeaiter A;Golding S;Bordogna W;Han J.-Y;Chih-Hsin Yang;Tessmer A;Dansin E;De Pas T;Crino L;Duruisseaux M;Moro-Sibilot D.L;Chiappori A;Kim D.-W;De Petris L;Camidge D.R;Socinski M.A;Gandhi L;Govindan R;Shaw A.T;Gadgeel S.M; Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:37Z Scientific Advances in Thoracic Oncology 2016 Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R.
臺大學術典藏 2020-05-26T09:26:37Z Scientific Advances in Thoracic Oncology 2016 Spigel D.R.;Hirsch F.R;Gandara D.R;Scagliotti G.V;Leighl N.B;Kelly R.J;Baas P;Tsao A;Rudin C.M;Faivre-Finn C;Wynes M.W;Peters S;Gettinger S;Horn L;Patel J.D;Costa D.B;Ahn M.-J;Shaw A.T;Sequist L.V;Chih-Hsin Yang;Johnson M;Kim D.-W;Solomon B;Senan S;Higgins K;Wu Y.-L;Wakelee H.A;Donington J;Asamura H;Lim E;Detterbeck F.C;Rami-Porta R;Dacic S;Bubendorf L;Yatabe Y;Mulshine J.L;Groen H.J.M;Field J.K;Jett J.R;Cummings K.M;Stone E.C.A;Soo R.A; Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R.
臺大學術典藏 2020-05-26T09:26:36Z Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer Shaw A.T.;Zeaiter A;Morcos P.N;Balas B;Bordogna W;Golding S;Dansin E;Ahn J.S;Popat S;Lena H;Crino L;Dingemans A.-M.C;Govindan R;Barlesi F;Kim D.-W;Gandhi L;Gadgeel S;De Petris L;Ou S.-H.I;Chih-Hsin Yang; CHIH-HSIN YANG; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T.
臺大學術典藏 2020-05-26T09:26:36Z Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer Shaw A.T.;Zeaiter A;Morcos P.N;Balas B;Bordogna W;Golding S;Dansin E;Ahn J.S;Popat S;Lena H;Crino L;Dingemans A.-M.C;Govindan R;Barlesi F;Kim D.-W;Gandhi L;Gadgeel S;De Petris L;Ou S.-H.I;Chih-Hsin Yang; CHIH-HSIN YANG; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T.
臺大學術典藏 2020-05-26T09:26:36Z Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non?�small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gadgeel S.;Kotb A;Zeaiter A;Bordogna W;Golding S;Do P;L?na H;Crino L;De Castro J;Chih-Hsin Yang;Hughes B.G.M;Camidge D.R;Kim D.-W;Dingemans A.-M.C;Barlesi F;Shaw A.T;Ignatius Ou S.-H;Gandhi L; Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S.
臺大學術典藏 2020-05-26T09:26:36Z Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non?�small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria Gadgeel S.;Kotb A;Zeaiter A;Bordogna W;Golding S;Do P;L?na H;Crino L;De Castro J;Chih-Hsin Yang;Hughes B.G.M;Camidge D.R;Kim D.-W;Dingemans A.-M.C;Barlesi F;Shaw A.T;Ignatius Ou S.-H;Gandhi L; Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S.
臺大學術典藏 2020-05-26T09:26:33Z Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Ou S.-H.I.;Kotb A;Gupta R;Liu S;Schulz M;De Marinis F;Kim D.-W;Dingemans A.-M.C;Chih-Hsin Yang;Crin? L;Barlesi F;Shaw A.T;Gadgeel S; Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:33Z Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Ou S.-H.I.;Kotb A;Gupta R;Liu S;Schulz M;De Marinis F;Kim D.-W;Dingemans A.-M.C;Chih-Hsin Yang;Crin? L;Barlesi F;Shaw A.T;Gadgeel S; Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:24Z Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies Gadgeel S;Shaw A.T;Barlesi F;Crino L;Chih-Hsin Yang;Dingemans A.-M;Kim D.-W;Marinis F;Schulz M;Liu S;Gupta R;Smoljanovic V;Ou S.-H.I.; Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:24Z Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies Gadgeel S;Shaw A.T;Barlesi F;Crino L;Chih-Hsin Yang;Dingemans A.-M;Kim D.-W;Marinis F;Schulz M;Liu S;Gupta R;Smoljanovic V;Ou S.-H.I.; Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I.
臺大學術典藏 2020-05-26T09:26:17Z Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou S.-H.I;Gadgeel S.M;Barlesi F;Chih-Hsin Yang;De Petris L;Kim D.-W;Govindan R;Dingemans A.-M;Crino L;L?na H;Popat S;Ahn J.S;Dansin E;Mitry E;M?ller B;Bordogna W;Balas B;Morcos P.N;Shaw A.T.; Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T.
臺大學術典藏 2020-05-26T09:26:17Z Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou S.-H.I;Gadgeel S.M;Barlesi F;Chih-Hsin Yang;De Petris L;Kim D.-W;Govindan R;Dingemans A.-M;Crino L;L?na H;Popat S;Ahn J.S;Dansin E;Mitry E;M?ller B;Bordogna W;Balas B;Morcos P.N;Shaw A.T.; Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T.
臺大學術典藏 2020-05-25T07:35:09Z Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R.
臺大學術典藏 2020-05-25T07:35:08Z Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations Solomon B.J; Martini J.-F; Ou S.-H.I; Chiari R; Soo R.A; Bearz A; Li S; Thurm H; Chia-Chi Lin; Riely G.J; Bauer T.M; Shaw A.T.
臺大學術典藏 2020-05-25T07:35:07Z ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F.
臺大學術典藏 2020-05-25T07:35:07Z Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J
臺大學術典藏 2020-05-25T07:35:02Z Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C.
臺大學術典藏 2020-05-25T07:35:02Z Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C.

Showing items 1-25 of 31  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page